reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AVAV AEROVIRONMENT INC.
KFS KINGSWAY FINANCIAL SERVICES
PAYS PAYSIGN INC
PRCH PORCH GROUP INC (A)
SPNT SIRIUSPOINT LTD
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
OSCR OSCAR HEALTH
JOBY JOBY AVIATION INC
COIN COINBASE GLOBAL INC
EVEX EVE HOLDING INC
GCT GIGACLOUD TECHNOLOGY INC
CRBG COREBRIDGE FINANCIAL INC.
SGHC SUPER GROUP (SGHC) LIMITED
RDW REDWIRE CORP
DAVE DAVE INC
GRALV GRAIL INC.
SMCI SUPER MICRO COMPUTER INC.
EVTL VERTICAL AEROSPACE LTD.
ANET ARISTA NETWORKS INC
OWLT OWLET INC
ESP BROMPTON ENERGY SPLIT CORP
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listi...
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into em...
Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt
Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, hat heute den Preis eines geplanten öffentlichen Zeichnungsangebots von 5.263.158 Stammaktien zu einem öffentlichen Angebotspreis von 57,00 USD je Aktie (die „Angebotsaktien“) bekanntgegebe...
Merus N.V. annonce la fixation du prix de l’offre publique d’actions o...
Merus N.V. annonce la fixation du prix de l’offre publique d’actions ordinaires UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus », la « Société », « nous » ou « notre/nos », une société spécialisée dans l’oncologie développant des anticorps multispécifiques pleine longueur innovants et des conjugués anticorps-médicaments appelés Biclonics®, Triclonics® et ADClonics®, fixe ce jour le prix de lancement de ses 5 263 158 actions ordinaires à 57,00 dollars chacune dans le cadre de son offre publique de souscri...
Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammakti...
Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammaktien bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, gab heute den Start eines geplanten öffentlichen Zeichnungsangebots seiner Stammaktien (die „Angebotsaktien“) bekannt. Alle Stammaktien werden von Merus angeboten. Darüber hinaus ...
Merus N.V. annonce une offre publique de souscription d’actions ordina...
Merus N.V. annonce une offre publique de souscription d’actions ordinaires UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des anticorps multispécifiques innovants et des conjugués anticorps-médicaments (Biclonics®, Triclonics® et ADClonics®), a annoncé aujourd’hui le lancement d’une offre publique de souscription de ses actions ordinaires (les « Actions de l’offre »). Toutes les actions ordinaires sont proposées par Merus. E...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update June: Removing Merus, Shurgard and Adyen ...
In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
DIE D'IETEREN SA
SOF SOFINA SA
ROYAL VOPAK NV
MELE MELEXIS NV
KIN KINEPOLIS GROUP NV
MRUS MERUS B V
ADYEN ADYEN NV
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
- Thomas Vranken
Merus Raises $ 300m through public offering
Merus has announced a public offering of 5.26m shares at $57 per share, an 8.6% discount to the previous close, to raise approx. $300 million in gross proceeds. The proceeds from the offering will fund clinical and preclinical development, technology advancement, and general corporate needs. Following strong ASCO 2025 data and a resulting share price increase, the transaction strengthens Merus' financial position beyond its solid 1Q25 cash position of $638m. We have raised the probability of suc...
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Thomas Vranken
- Wim Lewi
Merus N.V. Announces Pricing of Public Offering of Common Shares
Merus N.V. Announces Pricing of Public Offering of Common Shares UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to ...
Merus N.V. Announces Proposed Public Offering of Common Shares
Merus N.V. Announces Proposed Public Offering of Common Shares UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day opti...
Merus to Present at Upcoming Investor Conferences
Merus to Present at Upcoming Investor Conferences UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences: William Blair 45th Annual Growth Stock Conference: Tuesday, June 3 at 8:40 a.m. CT/9:40 a.m. ETJefferies Global Healthcare Conference: Wednesday, June 4 at ...
Merus hält Vorträge auf bevorstehenden Investorenkonferenzen
Merus hält Vorträge auf bevorstehenden Investorenkonferenzen UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge sowie Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, gab heute bekannt, dass Dr. Bill Lundberg, Präsident und Chief Executive Officer von Merus, an den folgenden Investorenkonferenzen teilnehmen wird: William Blair 45th Annual Growth Stock Conference: Dienstag, 3. Juni um 8:40 Uhr. CST/11:40 U...
Merus annonce sa participation aux prochaines journées Investisseurs
Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 27 mai 2025 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), une société d’oncologie développant des anticorps multispécifiques de pleine longueur novateurs et des conjugués anticorps-médicaments (Biclonics®, Triclonics® et ADClonics®), a annoncé ce jour la présence de son PDG Bill Lundberg, docteur en médecine, aux journées Investisseurs suivantes : 45e conférence annuelle William Blair sur les actions de croissance : mardi 3 juin à 8 h 40, heure centrale/9 h 40 heure de l’Es...
- Thomas Vranken
Dynamic Top Pick List update Removing Merus
Last week, Merus announced solid interim Phase 2 data to be presented at the ASCO 2025 conference with its lead asset petosemtamab in combination with current standard of care Keytruda for first-line treatment of patients with head and neck cancer (PD-L1+ refractory/ metastatic (r/m) head and neck squamous cell carcinoma (HNSCC)), a cancer type that is notoriously hard to treat. The updated dataset contains more patients than last year's presentation and featured a 63% overall response rate (27/...
Vorläufige Ergebnisse von Merus zu Petosemtamab mit Pembrolizumab zeig...
Vorläufige Ergebnisse von Merus zu Petosemtamab mit Pembrolizumab zeigen robuste Wirksamkeit und Dauerhaftigkeit bei der Erstlinienbehandlung von PD-L1-positivem r/m HNSCC - 63%ige Ansprechrate bei 24 auswertbaren Patienten beobachtet - 79%ige Gesamtüberlebensrate nach 12 Monaten; 9 Monate medianes progressionsfreies Überleben - Telefonkonferenz am Donnerstag, 22. Mai, um 17:30 Uhr (Eastern Time) UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, May 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Onkologieunternehmen, das innovative multispe...
Les données intermédiaires du pétosemtamab de Merus en association ave...
Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent une réelle efficacité et une bonne durabilité dans le traitement de 1re ligne contre le CETC r/m PD-L1+ - Taux de réponse de 63 % observé chez les 43 patients évaluables - Taux de survie général de 79 % au bout de 12 mois ; survie sans progression de niveau moyen à 9 mois - Conférence téléphonique le jeudi 22 mai à 17 h 30 heure de l’Est UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 24 mai 2025 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), ci-après « Merus », « la Société », « nous » ou «...
- Thomas Vranken
Merus Updated ASCO data confirm best-in-class potential in 1L HNSCC
Merus reported solid interim Ph2 data for ASCO 2025 with peto combo with Keytruda in 1L PD-L1+ r/m HNSCC, tracking nicely in line with last year's ASCO data. The updated dataset featured a 63% ORR (incl. 6 CRs), a mPFS of 9 months, and 12-month survival rate of 79%. Responses were observed across PD-L1 levels and HPV+ subgroups, and the treatment showed no new safety signals. The data support petosemtamab's potential to outperform Keytruda monotherapy and become the new gold standard in head an...
- Guy Sips
- Hilde Van Boxstael
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robus...
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC - 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and A...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.